ClinicalTrials.Veeva

Menu

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study

Mayo Clinic logo

Mayo Clinic

Status

Enrolling

Conditions

Major Depressive Disorder
Mild Cognitive Impairment
Bipolar Disorder

Treatments

Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.

Study type

Observational

Funder types

Other

Identifiers

NCT06897670
24-012395

Details and patient eligibility

About

The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.

Full description

This study will examine cerebral hemodynamic patterns in individuals with mood disorders (major depressive disorder and bipolar disorder) and cognitive disorders (mild cognitive impairment) using functional near-infrared spectroscopy (fNIRS). The primary goal is to compare hemodynamic patterns between these groups, while the secondary goal is to explore correlations between these patterns and symptom severity based on standardized clinical assessments. Additionally, electrophysiological data, including photoplethysmography (PPG) and electrocardiogram (ECG), will be analyzed to investigate autonomic nervous system activity and its relationship with cerebral hemodynamics.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

General Inclusion Criteria (across all diagnostic groups):

  • 18 years and older
  • Ability to provide written informed consent
  • Adequate cognitive and language abilities to understand and complete study tasks, including clinical assessments and fNIRS procedures
  • Confirmed clinical diagnosis of major depressive disorder, bipolar disorder, or mild cognitive impairment (MCI)
  • Stable psychiatric or cognitive condition, without acute episodes requiring immediate intervention

Specific Inclusion Criteria (for diagnostic groups):

  • Healthy control

    o No past or current psychiatric or cognitive disorder

  • Major depressive disorder (MDD):

    • Diagnosis of major depressive disorder, confirmed through clinical evaluation.
    • No history of bipolar disorder or psychotic symptoms.
  • Bipolar disorder:

    o Diagnosis of bipolar disorder I or II, confirmed through clinical evaluation.

  • Mild Cognitive Impairment (MCI):

    • Pre-existing clinical diagnosis of mild cognitive impairment, supported by neuropsychological testing and/or MRI, PET scan data.
    • No history of major psychiatric disorders, such as major depression, bipolar disorder or schizophrenia.

Exclusion Criteria

General Exclusion Criteria (across all diagnostic groups):

  • Active primary psychotic or substance use disorders (except nicotine dependence) within the past year
  • Any severe or unstable medical condition that could interfere with participation or data collection
  • Any active neurological condition (including seizure disorder, traumatic brain injury, stroke) that could affect cognitive functioning or brain imaging results
  • Inability to comply with study procedures, including cognitive testing, fNIRS assessment, or other assessments required by the protocol
  • Pregnant women will be excluded due to potential physiological changes that could affect study outcomes

Specific Exclusion Criteria (for diagnostic groups):

  • Healthy control

    o Any past or current psychiatric or cognitive disorder

  • Major depressive disorder (MDD):

    • Diagnosis of bipolar disorder or schizophrenia.
    • Brain stimulation therapy within the past 3 months.
  • Bipolar disorder:

    o Diagnosis of schizophrenia or schizoaffective disorder.

  • Mild Cognitive Impairment (MCI):

    • Diagnosis of dementia.
    • Significant cognitive impairment preventing understanding or completion of study tasks.

Trial design

200 participants in 4 patient groups

Healthy Controls
Description:
o No past or current psychiatric or cognitive disorder.
Treatment:
Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
Major Depressive Disorder
Description:
* Diagnosis of major depressive disorder, confirmed through clinical evaluation. * No history of bipolar disorder or psychotic symptoms.
Treatment:
Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
Bipolar Disorder
Description:
o Diagnosis of bipolar disorder I or II, confirmed through clinical evaluation.
Treatment:
Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
Mild Cognitive Impairment (MCI)
Description:
* Pre-existing clinical diagnosis of mild cognitive impairment, supported by neuropsychological testing and/or MRI, PET scan data. * No history of major psychiatric disorders, such as major depression, bipolar disorder or schizophrenia.
Treatment:
Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.

Trial contacts and locations

1

Loading...

Central trial contact

Sarah M. Williams

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems